Organon & Co. (OGN)

Apr 1, 2025, 7:30 AM EDT - 22 hours ago

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

Mar 28, 2025, 6:00 AM EDT - 4 days ago

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Mar 17, 2025, 10:58 PM EDT - 15 days ago

Why Organon Is A Top Pick For Income Investors

Mar 8, 2025, 9:00 AM EST - 24 days ago

New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Feb 19, 2025, 8:09 AM EST - 5 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

BMY PFE

Feb 17, 2025, 7:45 AM EST - 6 weeks ago

Organon: 7% Yield With A Bargain Basement Valuation

Feb 13, 2025, 12:47 PM EST - 6 weeks ago

Organon & Co. (OGN) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 7:30 AM EST - 6 weeks ago

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

Jan 23, 2025, 7:30 AM EST - 2 months ago

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Jan 17, 2025, 1:03 PM EST - 2 months ago

Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield

Jan 13, 2025, 9:38 PM EST - 2 months ago

Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)

Dec 19, 2024, 7:30 AM EST - 3 months ago

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 1:40 PM EST - 4 months ago

Final Trades: Amazon, American Express and Organon

AMZN AXP

Nov 14, 2024, 12:42 PM EST - 4 months ago

Organon: 7% Yield, 4x P/E, Big Upside Potential

Nov 13, 2024, 8:30 AM EST - 4 months ago

Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)

Oct 31, 2024, 12:28 PM EDT - 5 months ago

Organon & Co. (OGN) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:30 AM EDT - 5 months ago

Organon Reports Results for the Third Quarter Ended September 30, 2024

Oct 28, 2024, 9:25 AM EDT - 5 months ago

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Oct 22, 2024, 7:36 AM EDT - 5 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

ARQT TMDX

Oct 21, 2024, 2:12 PM EDT - 5 months ago

5 Stocks to Buy for a Harris Presidency

MSFT NEE RIVN STRL

Oct 9, 2024, 7:30 AM EDT - 6 months ago

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

Oct 2, 2024, 1:35 PM EDT - 6 months ago

Final Trades: Organon, Howmet and the PSQ

HWM PSQ

Sep 18, 2024, 3:20 PM EDT - 6 months ago

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

ROIV

Sep 18, 2024, 10:59 AM EDT - 6 months ago

Roivant Flips a Skin Drug to Organon

ROIV

Sep 18, 2024, 7:39 AM EDT - 6 months ago

Organon to buy therapy developer Dermavant for up to $1.2 billion

Sep 18, 2024, 7:30 AM EDT - 6 months ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

ROIV

Sep 6, 2024, 1:46 PM EDT - 7 months ago

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

TEVA

Aug 20, 2024, 7:30 AM EDT - 8 months ago

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Aug 6, 2024, 11:00 AM EDT - 8 months ago

Organon & Co. (OGN) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 8 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2024

Aug 3, 2024, 7:45 AM EDT - 8 months ago

Top 4 stocks that could thrive if Kamala Harris wins the 2024 US election

RIVN TLRY ZS

Jul 29, 2024, 9:41 PM EDT - 8 months ago

Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum

Jul 20, 2024, 8:00 AM EDT - 9 months ago

20 value stocks with high dividend yields and expected room to raise payouts

AM BEN CMA COLB CWEN EPR KSS

Jul 9, 2024, 7:30 AM EDT - 9 months ago

Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024

May 24, 2024, 11:38 AM EDT - 11 months ago

CUPE 37 Members Reject City of Calgary Wage Package

May 24, 2024, 6:00 AM EDT - 11 months ago

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

May 11, 2024, 6:58 AM EDT - 11 months ago

Organon Graduates From Spinoff Skepticism, With A Yield Above 5%

May 7, 2024, 8:20 PM EDT - 11 months ago

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

May 7, 2024, 12:43 PM EDT - 11 months ago

Four Reasons Why Organon Stock Is A Good Buy

May 7, 2024, 7:58 AM EDT - 11 months ago

Organon Announces Proposed $1.0 Billion Senior Notes Offering

May 2, 2024, 11:09 AM EDT - 11 months ago

Organon & Co. (OGN) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:30 AM EDT - 11 months ago

Organon Reports Results for the First Quarter Ended March 31, 2024

Apr 8, 2024, 6:15 AM EDT - 1 year ago

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

Apr 8, 2024, 6:00 AM EDT - 1 year ago

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Feb 20, 2024, 8:00 AM EST - 1 year ago

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

Feb 15, 2024, 12:06 PM EST - 1 year ago

Organon & Co. (OGN) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 7:30 AM EST - 1 year ago

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

Feb 1, 2024, 7:30 AM EST - 1 year ago

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024

Jan 9, 2024, 10:55 PM EST - 1 year ago

Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Jan 8, 2024, 7:30 AM EST - 1 year ago

Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook